Pulmonary Disease, Chronic Obstructive
Conditions
Brief summary
A retrospective analysis study in COPD patients for an exact follow-up period of 12 months (in subgroup analyses: 24 and 36 months); censoring of patients will only be done in case a patient died during the respective follow-up period.
Interventions
None listed
Sponsors
Boehringer Ingelheim
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* All patients who were continuously insured by the sickness fund for the entire period (01/01/2013-30/06/2018) or, in case a patient deceased after index date, for the time until death * A patient will be included as an incident COPD patient if either a hospital documented at least one COPD diagnosis (International Statistical Classification of Diseases and Related Health Problems (ICD-10 J 44.-) or a specialist (pneumologist) documented at least 2 confirmed COPD diagnoses (above ICD-10) code) in two different quarters; the first of the above diagnoses is defined as index diagnosis; inclusion period is defined as lasting from 01/01/2014 until 30/06/2017 * Patients should not have received any COPD diagnosis (ICD-10 J44.-) or any COPD-associated medication in the 12 months pre-index period * Patient should have, at date of incident COPD diagnosis (index date), an age of at least 40 years
Exclusion criteria
* Patients received , at least one confirmed inpatient asthma diagnosis or two confirmed outpatient diagnoses of asthma (ICD-10: J45) by pneumologists
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Description of Real-life Drug Treatment After Incident Diagnosis - COPD-12 Sample | Up to 12 months after the index date. | Description of real-life drug treatment in patients with newly diagnosed (incident) chronic obstructive pulmonary disease (COPD) in the first 12 months after the index date (date of incident (first) diagnosis of COPD). Reported is the percentage of patients per treatment and therapy line. The arms are not mutually exclusive, as patients switched to another treatment during follow-up period. COPD-12 sample: Patients with chronic obstructive pulmonary disease (COPD) included in german claims database between april 2015 and march 2018, with follow-up of 12 months since index date (COPD-12). LABA: Long-acting beta agonist; LAMA: Long-acting muscarinic antagonist, ICS: Inhaled corticosteroids. |
| Description of Real-life Drug Treatment After Incident Diagnosis - COPD-24 Sample | Up to 24 months after the index date. | Description of real-life drug treatment in patients with newly diagnosed (incident) chronic obstructive pulmonary disease (COPD) in the first 24 months after the index date (date of incident (first) diagnosis of COPD). Reported is the percentage of patients per treatment and therapy line. The arms are not mutually exclusive, as patients switched to another treatment during follow-up period. COPD-24 sample: Patients with chronic obstructive pulmonary disease (COPD) included in german claims database between april 2015 and march 2018, with follow-up of 24 months since index date (COPD-24). LABA: Long-acting beta agonist; LAMA: Long-acting muscarinic antagonist, ICS: Inhaled corticosteroids. |
| Description of Real-life Drug Treatment After Incident Diagnosis - COPD-36 Sample | Up to 36 months after the index date. | Description of real-life drug treatment in patients with newly diagnosed (incident) chronic obstructive pulmonary disease (COPD) in the first 36 months after the index date (date of incident (first) diagnosis of COPD). Reported is the percentage of patients per treatment and therapy line. The arms are not mutually exclusive, as patients switched to another treatment during follow-up period. COPD-36 sample: Patients with chronic obstructive pulmonary disease (COPD) included in german claims database between april 2015 and march 2018, with follow-up of 36 months since index date (COPD-36). LABA: Long-acting beta agonist; LAMA: Long-acting muscarinic antagonist, ICS: Inhaled corticosteroids. |
| Number of Observed Treatment Lines - COPD-12, COPD-24, COPD-36 and COPD-FULL Sample | Up to 12, 24, 36 and 48 months after index date for COPD-12, COPD-24, COPD-36 and COPD-FULL sample respectively. | Number of treatment lines an observed patient received in the first 12/24/36 and 48 months after incident diagnosis. |
| Percentage of Patients Per Most Frequently Prescribed Non-COPD Agents in COPD-FULL, COPD-12, COPD-24 and COPD-36 Samples | Up to 12, 24, 36 and 48 months after index date for COPD-12, COPD-24, COPD-36 and COPD-FULL sample respectively. | Percentage of participants per most frequently prescribed non-COPD agents in the first 12/24/36 and 48 months after incident diagnosis. GERD: Gastroesophageal reflux disease. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Yearly Hospitalizations in COPD-12, COPD-24 and COPD-36 Samples | Up to 12, 24 and 36 months after index date for COPD-12, COPD-24 and COPD-36 sample respectively. | Description of health-care resource use in the first 12/24/36 months after incident diagnosis: Number of yearly hospitalizations (inpatient treatment). Following categories of inpatient treatment are reported: Number of yearly hospitalizations with exacerbations (J44.1); Number of yearly hospitalizations with exacerbations, any COPD diagnosis (J44); Number of yearly hospitalizations with non-COPD diagnosis. Results are reported by follow-up time and available Disease Management Program (DMP) data. |
| Time to First All-cause Hospitalization in COPD-12, COPD-24, COPD-36 Samples | Up to 12, 24 and 36 months after index date for COPD-12, COPD-24 and COPD-36 sample respectively. | Description of health-care resource use in the first 12/24/36 months after incident diagnosis in patients with chronic obstructive pulmonary disease (COPD). Reported is time to first all-cause hospitalization in days (inpatient treatment). |
| Description of Direct Treatment Cost After Incident Diagnosis in COPD-12, COPD-24 and COPD-36 Samples | Up to 12, 24 and 36 months after index date for COPD-12, COPD-24 and COPD-36 sample respectively. | Description of direct treatment cost in the first 12/24/36 months after incident diagnosis - yearly costs in incident chronic obstructive pulmonary disease (COPD) patients. LTOT: Long-Term Oxygen Therapy. |
| Prescription of Medication in COPD-12, COPD-24 and COPD-36 Samples | Up to 12, 24 and 36 months after index date for COPD-12, COPD-24 and COPD-36 sample respectively. | Description of health-care resource use in the first 12/24/36 months after incident diagnosis - Prescription of medication. Top-5 prescription of non-COPD medication: Beta-blocking agents; Anti-thrombotic agents; Other analgesics & antipyretics; High-ceiling diuretics; Drugs for peptic ulcer or Gastroesophageal reflux disease (GERD). Other prescriptions: Antibiotics for systemic use (ATC J02AA); Antibiotics + corticosteroids (ATC D07C). Reported is number of yearly prescription. |
| Percentage of Incident COPD-patients With Initial Treatment Not in Line Treatment Guideline - COPD-12 Sample | At index date. | Percentage of incident chronic obstructive pulmonary disease (COPD) patients with initial drug treatment not in line with 2012/2018 german guidelines. Results are reported for COPD-12 sample. According to guidelines the initial treatment with long-acting bronchodilators should generally not include use of Inhaled corticosteroids (ICS) (both guidelines). Based on the 2012 guideline, a therapy with long-acting bronchodilators should not start with a combination of Long-acting beta agonist (LABA) + Long-acting muscarinic antagonist (LAMA) or triple therapy of LAMA+LABA+ ICS. |
| Time From Index Date Until Start of Long-term Oxygen Therapy (LTOT) - COPD-12, COPD-24 and COPD-36 Samples | Up to 12, 24 and 36 months after index date for COPD-12, COPD-24 and COPD-36 sample respectively. | Time from index date until start of long-term oxygen therapy (LTOT) in days in the first 12/24/36 months after incident diagnosis. |
| Time From Index Date Until First Exacerbation - COPD-FULL, COPD-12, COPD-24 and COPD-36 | Up to 12, 24, 36 and 48 months after index date for COPD-12, COPD-24, COPD-36 and COPD-FULL sample respectively. | Time from index date until first exacerbation, in the first 12/24/36/48 months after incident diagnosis. Only severe exacerbations leading to an inpatient hospitalization after index date (documented as main diagnosis: ICD-10 J44.1) are considered. |
| Average Number of Yearly Exacerbations During Follow-up - COPD-FULL, COPD-12, COPD-24 and COPD-36 | Up to 12, 24, 36 and 48 months after index date for COPD-12, COPD-24, COPD-36 and COPD-FULL sample respectively. | Average number of yearly exacerbations in the first 12/24/36 and 48 months after incident diagnosis. |
| Average Medication Costs Per Year - COPD-12, COPD-24 and COPD-36 | Up to 12, 24 and 36 months after index date for COPD-12, COPD-24 and COPD-36 respectively. | Description of yearly costs in incident chronic obstructive pulmonary disease (COPD) patients. Cost of non-COPD-medication are based on the top-10 prescribed on non-COPD drug therapies. |
| Number of Patients With Long Term Oxygen Therapy (LTOT) in COPD-12, COPD-24 and COPD-36 Samples | Up to 12, 24 and 36 months after index date for COPD-12, COPD-24 and COPD-36 sample respectively. | Description of health-care resource use in the first 12/24/36 months after incident diagnosis - Number of Patients with Long Term Oxygen Therapy (LTOT). |
| Percentage of Incident COPD-patients With Treatment Not in Line Treatment Guideline - COPD-12 Sample (Triple Therapy) | At first day of triple therapy prescription, (which is not the index date), up to 12 months. | Percentage of incident chronic obstructive pulmonary disease (COPD) patients with drug treatment not in line with 2012/2018 german guidelines. Results are reported for COPD-12 sample, who received triple therapy (Long-acting beta agonist (LABA) + Long-acting muscarinic antagonist (LAMA) + Inhaled corticosteroids (ICS)) within the first 12 months after incident diagnosis. According to both guidelines (2012/2018) a triple combination treatment should not be prescribed if only 1 or less confirmed outpatient diagnoses and no inpatient diagnosis of a COPD exacerbation (ICD-10 J44.1) before date of prescription of a triple therapy. FEV1: Forced expiratory volume (in 1 second). |
| Percentage of Incident COPD-patients With Treatment Not in Line Treatment Guideline - COPD-12 Sample (Escalation Therapy) | Up to 12 months after index date. | Percentage of incident chronic obstructive pulmonary disease (COPD) patients with drug treatment not in line with 2012/2018 german guidelines. Results are reported for patients in COPD-12 sample, with treatment escalation (mono therapy to Long-acting beta agonist (LABA)/ Long-acting muscarinic antagonist (LAMA)/ Inhaled corticosteroids (ICS), LABA/ICS or LAMA/LABA to LABA/LAMA/ICS) within the first 12 months after index date. According to guidelines patients should not receive a treatment intensification without any previous visit of a pneumologist or hospital (same quarter or previous quarter). |
| Percentage of Patients With Exacerbations After Incident Diagnosis in COPD-12, COPD-24, COPD-36 and COPD-FULL Samples | Up to 12,24, 36 and 48 months after index date, for COPD-12, COPD-24, COPD-36 and COPD-FULL sample respectively. | Description of exacerbation (severe exacerbations associated with hospitalizations) frequency of patients with newly diagnosed (incident) chronic obstructive pulmonary disease (COPD) in the first 12, 24, 36 and 48 months after incident diagnosis. Reported is the percentage of patients with exacerbations by the following categories: More or equal than one exacerbation (≥ 1) ; 1. exacerbation; 2. exacerbations; 3. exacerbations; more than 3 exacerbations (\> 3 exacerbations). |
| Number of Yearly Visits Per Outpatient Treatment in COPD-12, COPD-24 and COPD-36 Samples | Up to 12, 24 and 36 months after index date for COPD-12, COPD-24 and COPD-36 sample respectively. | Description of health-care resource use (HCRU) in the first 12/24/36 months after incident diagnosis - Number of yearly visits (outpatient treatment). Following categories are reported: Number of yearly general practitioner (GP) visits; Number of yearly pulmonologist visits; Number of yearly other specialist (primarily Ophthalmologist, Ear, Nose and Throat (ENT) specialist and Orthopedist) visits. Reported is the average number of yearly visits, per observed patient year. |
Countries
Germany
Participant flow
Recruitment details
A retrospective, non-interventional, longitudinal study including real-world data from german claims data (2015-2018) to describe the real-world drug treatment in patients of newly diagnosed chronic obstructive pulmonary disease (COPD).
Pre-assignment details
Only subjects that met all inclusion and none of the exclusion criteria were included in the study.
Participants by arm
| Arm | Count |
|---|---|
| COPD-FULL Sample Patients with incident chronic obstructive pulmonary disease (COPD) between April 2015 and March 2018 from German claims database were followed for up to 48 months. Patients were censored in case of death or loss to follow-up. | 17,464 |
| Total | 17,464 |
Baseline characteristics
| Characteristic | COPD-FULL Sample | — |
|---|---|---|
| Age, Continuous | 71.5 Years STANDARD_DEVIATION 12.3 | — |
| Race and Ethnicity Not Collected | — | — Participants |
| Sex/Gender, Customized Female | 41.4 Percentage of participants | — |
| Sex/Gender, Customized Male | 58.6 Percentage of participants | — |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 5,238 / 17,464 |
| other Total, other adverse events | 0 / 0 |
| serious Total, serious adverse events | 0 / 0 |
Outcome results
Primary
Description of Real-life Drug Treatment After Incident Diagnosis - COPD-12 Sample
Description of real-life drug treatment in patients with newly diagnosed (incident) chronic obstructive pulmonary disease (COPD) in the first 12 months after the index date (date of incident (first) diagnosis of COPD). Reported is the percentage of patients per treatment and therapy line. The arms are not mutually exclusive, as patients switched to another treatment during follow-up period. COPD-12 sample: Patients with chronic obstructive pulmonary disease (COPD) included in german claims database between april 2015 and march 2018, with follow-up of 12 months since index date (COPD-12). LABA: Long-acting beta agonist; LAMA: Long-acting muscarinic antagonist, ICS: Inhaled corticosteroids.
Time frame: Up to 12 months after the index date.
Population: All patients included in the COPD-12 sample, who received any long term-COPD treatment. Patients are reported by therapy line (arms are not mutually exclusive). The number of patients who received COPD-12 Fourth Line Therapy is less than 5% of the patient population (N=8238). As defined in the protocol, data collected only for treatment pattern combinations that were observed in \>5% in patient population.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| COPD-12 - First Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-12 Sample | LAMA | 25.0 Percentage of Patients |
| COPD-12 - First Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-12 Sample | LABA + LAMA | 35.6 Percentage of Patients |
| COPD-12 - First Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-12 Sample | LAMA + ICS | 16.3 Percentage of Patients |
| COPD-12 - First Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-12 Sample | LABA | 8.5 Percentage of Patients |
| COPD-12 - First Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-12 Sample | LABA + LAMA + ICS | 8.1 Percentage of Patients |
| COPD-12 - First Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-12 Sample | ICS | 4.2 Percentage of Patients |
| COPD-12 - First Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-12 Sample | Other (Methylxanthine, LAMA+ICS, LABA+LAMA+Methyl-xanthine) | 2.3 Percentage of Patients |
| COPD-12 - Second Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-12 Sample | LABA | 5.4 Percentage of Patients |
| COPD-12 - Second Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-12 Sample | Other (Methylxanthine, LAMA+ICS, LABA+LAMA+Methyl-xanthine) | 9.0 Percentage of Patients |
| COPD-12 - Second Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-12 Sample | LABA + LAMA | 30.3 Percentage of Patients |
| COPD-12 - Second Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-12 Sample | LAMA + ICS | 14.3 Percentage of Patients |
| COPD-12 - Second Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-12 Sample | LAMA | 11.3 Percentage of Patients |
| COPD-12 - Second Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-12 Sample | LABA + LAMA + ICS | 24.8 Percentage of Patients |
| COPD-12 - Second Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-12 Sample | ICS | 4.8 Percentage of Patients |
| COPD-12 - Third Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-12 Sample | LAMA | 10.3 Percentage of Patients |
| COPD-12 - Third Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-12 Sample | LAMA + ICS | 13.6 Percentage of Patients |
| COPD-12 - Third Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-12 Sample | ICS | 6.1 Percentage of Patients |
| COPD-12 - Third Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-12 Sample | Other (Methylxanthine, LAMA+ICS, LABA+LAMA+Methyl-xanthine) | 9.4 Percentage of Patients |
| COPD-12 - Third Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-12 Sample | LABA + LAMA + ICS | 25.8 Percentage of Patients |
| COPD-12 - Third Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-12 Sample | LABA + LAMA | 29.1 Percentage of Patients |
| COPD-12 - Third Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-12 Sample | LABA | 5.6 Percentage of Patients |
Primary
Description of Real-life Drug Treatment After Incident Diagnosis - COPD-24 Sample
Description of real-life drug treatment in patients with newly diagnosed (incident) chronic obstructive pulmonary disease (COPD) in the first 24 months after the index date (date of incident (first) diagnosis of COPD). Reported is the percentage of patients per treatment and therapy line. The arms are not mutually exclusive, as patients switched to another treatment during follow-up period. COPD-24 sample: Patients with chronic obstructive pulmonary disease (COPD) included in german claims database between april 2015 and march 2018, with follow-up of 24 months since index date (COPD-24). LABA: Long-acting beta agonist; LAMA: Long-acting muscarinic antagonist, ICS: Inhaled corticosteroids.
Time frame: Up to 24 months after the index date.
Population: All patients included in the COPD-24 sample, who received any long term-COPD treatment. Patients are reported by therapy line (arms are not mutually exclusive).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| COPD-12 - First Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-24 Sample | LABA + LAMA | 34.4 Percentage of Patients |
| COPD-12 - First Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-24 Sample | ICS | 4.9 Percentage of Patients |
| COPD-12 - First Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-24 Sample | LABA + LAMA + ICS | 7.5 Percentage of Patients |
| COPD-12 - First Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-24 Sample | LAMA | 24.6 Percentage of Patients |
| COPD-12 - First Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-24 Sample | Other (Methylxanthine, LAMA+ICS, LABA+LAMA+Methyl-xanthine) | 2.2 Percentage of Patients |
| COPD-12 - First Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-24 Sample | LAMA + ICS | 17.3 Percentage of Patients |
| COPD-12 - First Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-24 Sample | LABA | 9.2 Percentage of Patients |
| COPD-12 - Second Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-24 Sample | ICS | 4.6 Percentage of Patients |
| COPD-12 - Second Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-24 Sample | LABA | 5.0 Percentage of Patients |
| COPD-12 - Second Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-24 Sample | LAMA + ICS | 15.2 Percentage of Patients |
| COPD-12 - Second Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-24 Sample | LABA + LAMA + ICS | 24.9 Percentage of Patients |
| COPD-12 - Second Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-24 Sample | Other (Methylxanthine, LAMA+ICS, LABA+LAMA+Methyl-xanthine) | 8.2 Percentage of Patients |
| COPD-12 - Second Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-24 Sample | LAMA | 11.6 Percentage of Patients |
| COPD-12 - Second Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-24 Sample | LABA + LAMA | 30.6 Percentage of Patients |
| COPD-12 - Third Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-24 Sample | LABA | 5.6 Percentage of Patients |
| COPD-12 - Third Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-24 Sample | LABA + LAMA | 25.0 Percentage of Patients |
| COPD-12 - Third Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-24 Sample | LAMA | 11.3 Percentage of Patients |
| COPD-12 - Third Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-24 Sample | LAMA + ICS | 13.7 Percentage of Patients |
| COPD-12 - Third Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-24 Sample | LABA + LAMA + ICS | 28.7 Percentage of Patients |
| COPD-12 - Third Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-24 Sample | ICS | 4.9 Percentage of Patients |
| COPD-12 - Third Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-24 Sample | Other (Methylxanthine, LAMA+ICS, LABA+LAMA+Methyl-xanthine) | 10.9 Percentage of Patients |
| COPD-12 - Fourth Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-24 Sample | LAMA + ICS | 15.1 Percentage of Patients |
| COPD-12 - Fourth Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-24 Sample | Other (Methylxanthine, LAMA+ICS, LABA+LAMA+Methyl-xanthine) | 15.9 Percentage of Patients |
| COPD-12 - Fourth Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-24 Sample | ICS | 4.8 Percentage of Patients |
| COPD-12 - Fourth Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-24 Sample | LAMA | 10.3 Percentage of Patients |
| COPD-12 - Fourth Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-24 Sample | LABA + LAMA | 25.4 Percentage of Patients |
| COPD-12 - Fourth Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-24 Sample | LABA + LAMA + ICS | 23.9 Percentage of Patients |
| COPD-12 - Fourth Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-24 Sample | LABA | 4.8 Percentage of Patients |
Primary
Description of Real-life Drug Treatment After Incident Diagnosis - COPD-36 Sample
Description of real-life drug treatment in patients with newly diagnosed (incident) chronic obstructive pulmonary disease (COPD) in the first 36 months after the index date (date of incident (first) diagnosis of COPD). Reported is the percentage of patients per treatment and therapy line. The arms are not mutually exclusive, as patients switched to another treatment during follow-up period. COPD-36 sample: Patients with chronic obstructive pulmonary disease (COPD) included in german claims database between april 2015 and march 2018, with follow-up of 36 months since index date (COPD-36). LABA: Long-acting beta agonist; LAMA: Long-acting muscarinic antagonist, ICS: Inhaled corticosteroids.
Time frame: Up to 36 months after the index date.
Population: All patients included in the COPD-36 sample, who received any long term-COPD treatment. Patients are reported by therapy line (arms are not mutually exclusive).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| COPD-12 - First Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-36 Sample | LABA + LAMA | 31.3 Percentage of Patients |
| COPD-12 - First Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-36 Sample | ICS | 6.3 Percentage of Patients |
| COPD-12 - First Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-36 Sample | LABA + LAMA + ICS | 7.9 Percentage of Patients |
| COPD-12 - First Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-36 Sample | LAMA | 25.2 Percentage of Patients |
| COPD-12 - First Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-36 Sample | Other (Methylxanthine, LAMA+ICS, LABA+LAMA+Methyl-xanthine) | 2.2 Percentage of Patients |
| COPD-12 - First Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-36 Sample | LAMA + ICS | 17.8 Percentage of Patients |
| COPD-12 - First Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-36 Sample | LABA | 9.3 Percentage of Patients |
| COPD-12 - Second Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-36 Sample | ICS | 4.9 Percentage of Patients |
| COPD-12 - Second Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-36 Sample | LABA | 6.1 Percentage of Patients |
| COPD-12 - Second Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-36 Sample | LAMA + ICS | 15.5 Percentage of Patients |
| COPD-12 - Second Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-36 Sample | LABA + LAMA + ICS | 20.6 Percentage of Patients |
| COPD-12 - Second Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-36 Sample | Other (Methylxanthine, LAMA+ICS, LABA+LAMA+Methyl-xanthine) | 8.2 Percentage of Patients |
| COPD-12 - Second Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-36 Sample | LAMA | 12.5 Percentage of Patients |
| COPD-12 - Second Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-36 Sample | LABA + LAMA | 32.2 Percentage of Patients |
| COPD-12 - Third Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-36 Sample | LABA | 7.0 Percentage of Patients |
| COPD-12 - Third Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-36 Sample | LABA + LAMA | 27.7 Percentage of Patients |
| COPD-12 - Third Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-36 Sample | LAMA | 12.3 Percentage of Patients |
| COPD-12 - Third Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-36 Sample | LAMA + ICS | 13.3 Percentage of Patients |
| COPD-12 - Third Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-36 Sample | LABA + LAMA + ICS | 24.3 Percentage of Patients |
| COPD-12 - Third Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-36 Sample | ICS | 5.0 Percentage of Patients |
| COPD-12 - Third Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-36 Sample | Other (Methylxanthine, LAMA+ICS, LABA+LAMA+Methyl-xanthine) | 10.3 Percentage of Patients |
| COPD-12 - Fourth Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-36 Sample | LAMA + ICS | 16.0 Percentage of Patients |
| COPD-12 - Fourth Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-36 Sample | Other (Methylxanthine, LAMA+ICS, LABA+LAMA+Methyl-xanthine) | 19.3 Percentage of Patients |
| COPD-12 - Fourth Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-36 Sample | ICS | 5.0 Percentage of Patients |
| COPD-12 - Fourth Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-36 Sample | LAMA | 4.2 Percentage of Patients |
| COPD-12 - Fourth Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-36 Sample | LABA + LAMA | 29.4 Percentage of Patients |
| COPD-12 - Fourth Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-36 Sample | LABA + LAMA + ICS | 21.0 Percentage of Patients |
| COPD-12 - Fourth Line Therapy | Description of Real-life Drug Treatment After Incident Diagnosis - COPD-36 Sample | LABA | 5.0 Percentage of Patients |
Primary
Number of Observed Treatment Lines - COPD-12, COPD-24, COPD-36 and COPD-FULL Sample
Number of treatment lines an observed patient received in the first 12/24/36 and 48 months after incident diagnosis.
Time frame: Up to 12, 24, 36 and 48 months after index date for COPD-12, COPD-24, COPD-36 and COPD-FULL sample respectively.
Population: All patients with newly diagnosed (incident) COPD and who received any long-term COPD treatment. Incident COPD-patients are reported by follow-up period (12, 24, 36 and 48 months). Arms are not mutually exclusive.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| COPD-12 - First Line Therapy | Number of Observed Treatment Lines - COPD-12, COPD-24, COPD-36 and COPD-FULL Sample | 1.39 Treatment lines | Standard Deviation 0.83 |
| COPD-12 - Second Line Therapy | Number of Observed Treatment Lines - COPD-12, COPD-24, COPD-36 and COPD-FULL Sample | 1.43 Treatment lines | Standard Deviation 0.86 |
| COPD-12 - Third Line Therapy | Number of Observed Treatment Lines - COPD-12, COPD-24, COPD-36 and COPD-FULL Sample | 1.51 Treatment lines | Standard Deviation 0.97 |
| COPD-12 - Fourth Line Therapy | Number of Observed Treatment Lines - COPD-12, COPD-24, COPD-36 and COPD-FULL Sample | 1.61 Treatment lines | Standard Deviation 1.06 |
Primary
Percentage of Patients Per Most Frequently Prescribed Non-COPD Agents in COPD-FULL, COPD-12, COPD-24 and COPD-36 Samples
Percentage of participants per most frequently prescribed non-COPD agents in the first 12/24/36 and 48 months after incident diagnosis. GERD: Gastroesophageal reflux disease.
Time frame: Up to 12, 24, 36 and 48 months after index date for COPD-12, COPD-24, COPD-36 and COPD-FULL sample respectively.
Population: All patients with newly diagnosed (incident) chronic obstructive pulmonary disease. Incident COPD-patients were reported by follow-up time (12, 24, 36 and 48 months). Arms are not mutually exclusive.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| COPD-12 - First Line Therapy | Percentage of Patients Per Most Frequently Prescribed Non-COPD Agents in COPD-FULL, COPD-12, COPD-24 and COPD-36 Samples | Drugs for peptic ulcer or GERD | 37.9 Percentage of participants |
| COPD-12 - First Line Therapy | Percentage of Patients Per Most Frequently Prescribed Non-COPD Agents in COPD-FULL, COPD-12, COPD-24 and COPD-36 Samples | Anti-thrombotic agents | 41.1 Percentage of participants |
| COPD-12 - First Line Therapy | Percentage of Patients Per Most Frequently Prescribed Non-COPD Agents in COPD-FULL, COPD-12, COPD-24 and COPD-36 Samples | Other analgesics & antipyretics | 20.3 Percentage of participants |
| COPD-12 - First Line Therapy | Percentage of Patients Per Most Frequently Prescribed Non-COPD Agents in COPD-FULL, COPD-12, COPD-24 and COPD-36 Samples | High-ceiling diurectis | 37.9 Percentage of participants |
| COPD-12 - First Line Therapy | Percentage of Patients Per Most Frequently Prescribed Non-COPD Agents in COPD-FULL, COPD-12, COPD-24 and COPD-36 Samples | Beta-blocking agents | 45.9 Percentage of participants |
| COPD-12 - Second Line Therapy | Percentage of Patients Per Most Frequently Prescribed Non-COPD Agents in COPD-FULL, COPD-12, COPD-24 and COPD-36 Samples | High-ceiling diurectis | 40.4 Percentage of participants |
| COPD-12 - Second Line Therapy | Percentage of Patients Per Most Frequently Prescribed Non-COPD Agents in COPD-FULL, COPD-12, COPD-24 and COPD-36 Samples | Drugs for peptic ulcer or GERD | 41.8 Percentage of participants |
| COPD-12 - Second Line Therapy | Percentage of Patients Per Most Frequently Prescribed Non-COPD Agents in COPD-FULL, COPD-12, COPD-24 and COPD-36 Samples | Other analgesics & antipyretics | 20.5 Percentage of participants |
| COPD-12 - Second Line Therapy | Percentage of Patients Per Most Frequently Prescribed Non-COPD Agents in COPD-FULL, COPD-12, COPD-24 and COPD-36 Samples | Anti-thrombotic agents | 45.0 Percentage of participants |
| COPD-12 - Second Line Therapy | Percentage of Patients Per Most Frequently Prescribed Non-COPD Agents in COPD-FULL, COPD-12, COPD-24 and COPD-36 Samples | Beta-blocking agents | 51.9 Percentage of participants |
| COPD-12 - Third Line Therapy | Percentage of Patients Per Most Frequently Prescribed Non-COPD Agents in COPD-FULL, COPD-12, COPD-24 and COPD-36 Samples | High-ceiling diurectis | 43.3 Percentage of participants |
| COPD-12 - Third Line Therapy | Percentage of Patients Per Most Frequently Prescribed Non-COPD Agents in COPD-FULL, COPD-12, COPD-24 and COPD-36 Samples | Beta-blocking agents | 55.6 Percentage of participants |
| COPD-12 - Third Line Therapy | Percentage of Patients Per Most Frequently Prescribed Non-COPD Agents in COPD-FULL, COPD-12, COPD-24 and COPD-36 Samples | Anti-thrombotic agents | 49.4 Percentage of participants |
| COPD-12 - Third Line Therapy | Percentage of Patients Per Most Frequently Prescribed Non-COPD Agents in COPD-FULL, COPD-12, COPD-24 and COPD-36 Samples | Drugs for peptic ulcer or GERD | 48.0 Percentage of participants |
| COPD-12 - Third Line Therapy | Percentage of Patients Per Most Frequently Prescribed Non-COPD Agents in COPD-FULL, COPD-12, COPD-24 and COPD-36 Samples | Other analgesics & antipyretics | 29.7 Percentage of participants |
| COPD-12 - Fourth Line Therapy | Percentage of Patients Per Most Frequently Prescribed Non-COPD Agents in COPD-FULL, COPD-12, COPD-24 and COPD-36 Samples | Drugs for peptic ulcer or GERD | 53.2 Percentage of participants |
| COPD-12 - Fourth Line Therapy | Percentage of Patients Per Most Frequently Prescribed Non-COPD Agents in COPD-FULL, COPD-12, COPD-24 and COPD-36 Samples | Anti-thrombotic agents | 52.6 Percentage of participants |
| COPD-12 - Fourth Line Therapy | Percentage of Patients Per Most Frequently Prescribed Non-COPD Agents in COPD-FULL, COPD-12, COPD-24 and COPD-36 Samples | Beta-blocking agents | 57.8 Percentage of participants |
| COPD-12 - Fourth Line Therapy | Percentage of Patients Per Most Frequently Prescribed Non-COPD Agents in COPD-FULL, COPD-12, COPD-24 and COPD-36 Samples | High-ceiling diurectis | 43.7 Percentage of participants |
| COPD-12 - Fourth Line Therapy | Percentage of Patients Per Most Frequently Prescribed Non-COPD Agents in COPD-FULL, COPD-12, COPD-24 and COPD-36 Samples | Other analgesics & antipyretics | 36.7 Percentage of participants |
Secondary
Average Medication Costs Per Year - COPD-12, COPD-24 and COPD-36
Description of yearly costs in incident chronic obstructive pulmonary disease (COPD) patients. Cost of non-COPD-medication are based on the top-10 prescribed on non-COPD drug therapies.
Time frame: Up to 12, 24 and 36 months after index date for COPD-12, COPD-24 and COPD-36 respectively.
Population: All patients with newly diagnosed (incident) chronic obstructive pulmonary disease. Incident COPD-patients are reported by follow-up time (12, 24 and 36 months). Arms are not mutually exclusive.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| COPD-12 - First Line Therapy | Average Medication Costs Per Year - COPD-12, COPD-24 and COPD-36 | Cost of non-COPD-medication (in total) | 386.99 Euro per Year (€/Y) | Standard Deviation 713.16 |
| COPD-12 - First Line Therapy | Average Medication Costs Per Year - COPD-12, COPD-24 and COPD-36 | Cost of COPD-medication (in total) | 317.46 Euro per Year (€/Y) | Standard Deviation 392.69 |
| COPD-12 - Second Line Therapy | Average Medication Costs Per Year - COPD-12, COPD-24 and COPD-36 | Cost of COPD-medication (in total) | 292.03 Euro per Year (€/Y) | Standard Deviation 367.37 |
| COPD-12 - Second Line Therapy | Average Medication Costs Per Year - COPD-12, COPD-24 and COPD-36 | Cost of non-COPD-medication (in total) | 355.92 Euro per Year (€/Y) | Standard Deviation 884.92 |
| COPD-12 - Third Line Therapy | Average Medication Costs Per Year - COPD-12, COPD-24 and COPD-36 | Cost of COPD-medication (in total) | 273.50 Euro per Year (€/Y) | Standard Deviation 361.06 |
| COPD-12 - Third Line Therapy | Average Medication Costs Per Year - COPD-12, COPD-24 and COPD-36 | Cost of non-COPD-medication (in total) | 369.15 Euro per Year (€/Y) | Standard Deviation 2202.62 |
Secondary
Average Number of Yearly Exacerbations During Follow-up - COPD-FULL, COPD-12, COPD-24 and COPD-36
Average number of yearly exacerbations in the first 12/24/36 and 48 months after incident diagnosis.
Time frame: Up to 12, 24, 36 and 48 months after index date for COPD-12, COPD-24, COPD-36 and COPD-FULL sample respectively.
Population: All patients with newly diagnosed (incident) chronic obstructive pulmonary disease. Incident COPD-patients were reported by follow-up time (12, 24, 36 and 48 months). Arms are not mutually exclusive.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| COPD-12 - First Line Therapy | Average Number of Yearly Exacerbations During Follow-up - COPD-FULL, COPD-12, COPD-24 and COPD-36 | 0.16 Exacerbations | Standard Deviation 0.57 |
| COPD-12 - Second Line Therapy | Average Number of Yearly Exacerbations During Follow-up - COPD-FULL, COPD-12, COPD-24 and COPD-36 | 0.14 Exacerbations | Standard Deviation 0.56 |
| COPD-12 - Third Line Therapy | Average Number of Yearly Exacerbations During Follow-up - COPD-FULL, COPD-12, COPD-24 and COPD-36 | 0.16 Exacerbations | Standard Deviation 0.64 |
| COPD-12 - Fourth Line Therapy | Average Number of Yearly Exacerbations During Follow-up - COPD-FULL, COPD-12, COPD-24 and COPD-36 | 0.18 Exacerbations | Standard Deviation 0.7 |
Secondary
Description of Direct Treatment Cost After Incident Diagnosis in COPD-12, COPD-24 and COPD-36 Samples
Description of direct treatment cost in the first 12/24/36 months after incident diagnosis - yearly costs in incident chronic obstructive pulmonary disease (COPD) patients. LTOT: Long-Term Oxygen Therapy.
Time frame: Up to 12, 24 and 36 months after index date for COPD-12, COPD-24 and COPD-36 sample respectively.
Population: Patients with newly diagnosed (incident) chronic obstructive pulmonary disease (COPD). Incident COPD-patients were reported by follow-up time (12, 24 and 36 months) and available Disease Management Program (DMP)-data. Arms are not mutually exclusive.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| COPD-12 - First Line Therapy | Description of Direct Treatment Cost After Incident Diagnosis in COPD-12, COPD-24 and COPD-36 Samples | Total costs for GP visits | 456.77 Euro per Person-year |
| COPD-12 - First Line Therapy | Description of Direct Treatment Cost After Incident Diagnosis in COPD-12, COPD-24 and COPD-36 Samples | Total costs for pulmnologist visits | 72.52 Euro per Person-year |
| COPD-12 - First Line Therapy | Description of Direct Treatment Cost After Incident Diagnosis in COPD-12, COPD-24 and COPD-36 Samples | Total cost for hospitalizations with COPD-exacerbations | 398.86 Euro per Person-year |
| COPD-12 - First Line Therapy | Description of Direct Treatment Cost After Incident Diagnosis in COPD-12, COPD-24 and COPD-36 Samples | Total costs for hospitalizations with any non-COPD-diagnosis | 10180.93 Euro per Person-year |
| COPD-12 - First Line Therapy | Description of Direct Treatment Cost After Incident Diagnosis in COPD-12, COPD-24 and COPD-36 Samples | Inpatient cost (all-cause) | 10936.50 Euro per Person-year |
| COPD-12 - First Line Therapy | Description of Direct Treatment Cost After Incident Diagnosis in COPD-12, COPD-24 and COPD-36 Samples | Total costs for other outpatient specialist visits | 564.51 Euro per Person-year |
| COPD-12 - First Line Therapy | Description of Direct Treatment Cost After Incident Diagnosis in COPD-12, COPD-24 and COPD-36 Samples | Total costs for hospitalizations with any COPD-diagnosis | 755.57 Euro per Person-year |
| COPD-12 - First Line Therapy | Description of Direct Treatment Cost After Incident Diagnosis in COPD-12, COPD-24 and COPD-36 Samples | (Total) cost of outpatient visits (incl. costs for LTOT) | 1093.80 Euro per Person-year |
| COPD-12 - Second Line Therapy | Description of Direct Treatment Cost After Incident Diagnosis in COPD-12, COPD-24 and COPD-36 Samples | Total costs for hospitalizations with any COPD-diagnosis | 450.23 Euro per Person-year |
| COPD-12 - Second Line Therapy | Description of Direct Treatment Cost After Incident Diagnosis in COPD-12, COPD-24 and COPD-36 Samples | Inpatient cost (all-cause) | 7013.81 Euro per Person-year |
| COPD-12 - Second Line Therapy | Description of Direct Treatment Cost After Incident Diagnosis in COPD-12, COPD-24 and COPD-36 Samples | Total cost for hospitalizations with COPD-exacerbations | 228.28 Euro per Person-year |
| COPD-12 - Second Line Therapy | Description of Direct Treatment Cost After Incident Diagnosis in COPD-12, COPD-24 and COPD-36 Samples | Total costs for GP visits | 446.63 Euro per Person-year |
| COPD-12 - Second Line Therapy | Description of Direct Treatment Cost After Incident Diagnosis in COPD-12, COPD-24 and COPD-36 Samples | (Total) cost of outpatient visits (incl. costs for LTOT) | 1059.52 Euro per Person-year |
| COPD-12 - Second Line Therapy | Description of Direct Treatment Cost After Incident Diagnosis in COPD-12, COPD-24 and COPD-36 Samples | Total costs for pulmnologist visits | 67.30 Euro per Person-year |
| COPD-12 - Second Line Therapy | Description of Direct Treatment Cost After Incident Diagnosis in COPD-12, COPD-24 and COPD-36 Samples | Total costs for hospitalizations with any non-COPD-diagnosis | 6563.58 Euro per Person-year |
| COPD-12 - Second Line Therapy | Description of Direct Treatment Cost After Incident Diagnosis in COPD-12, COPD-24 and COPD-36 Samples | Total costs for other outpatient specialist visits | 545.59 Euro per Person-year |
| COPD-12 - Third Line Therapy | Description of Direct Treatment Cost After Incident Diagnosis in COPD-12, COPD-24 and COPD-36 Samples | Total cost for hospitalizations with COPD-exacerbations | 165.79 Euro per Person-year |
| COPD-12 - Third Line Therapy | Description of Direct Treatment Cost After Incident Diagnosis in COPD-12, COPD-24 and COPD-36 Samples | Total costs for hospitalizations with any COPD-diagnosis | 349.47 Euro per Person-year |
| COPD-12 - Third Line Therapy | Description of Direct Treatment Cost After Incident Diagnosis in COPD-12, COPD-24 and COPD-36 Samples | Total costs for hospitalizations with any non-COPD-diagnosis | 5417.19 Euro per Person-year |
| COPD-12 - Third Line Therapy | Description of Direct Treatment Cost After Incident Diagnosis in COPD-12, COPD-24 and COPD-36 Samples | Total costs for GP visits | 444.03 Euro per Person-year |
| COPD-12 - Third Line Therapy | Description of Direct Treatment Cost After Incident Diagnosis in COPD-12, COPD-24 and COPD-36 Samples | Total costs for pulmnologist visits | 61.67 Euro per Person-year |
| COPD-12 - Third Line Therapy | Description of Direct Treatment Cost After Incident Diagnosis in COPD-12, COPD-24 and COPD-36 Samples | (Total) cost of outpatient visits (incl. costs for LTOT) | 1052.53 Euro per Person-year |
| COPD-12 - Third Line Therapy | Description of Direct Treatment Cost After Incident Diagnosis in COPD-12, COPD-24 and COPD-36 Samples | Total costs for other outpatient specialist visits | 546.82 Euro per Person-year |
| COPD-12 - Third Line Therapy | Description of Direct Treatment Cost After Incident Diagnosis in COPD-12, COPD-24 and COPD-36 Samples | Inpatient cost (all-cause) | 5766.66 Euro per Person-year |
| COPD-12 - Fourth Line Therapy | Description of Direct Treatment Cost After Incident Diagnosis in COPD-12, COPD-24 and COPD-36 Samples | Total costs for hospitalizations with any non-COPD-diagnosis | 4657 Euro per Person-year |
| COPD-12 - Fourth Line Therapy | Description of Direct Treatment Cost After Incident Diagnosis in COPD-12, COPD-24 and COPD-36 Samples | (Total) cost of outpatient visits (incl. costs for LTOT) | 1179 Euro per Person-year |
| COPD-12 - Fourth Line Therapy | Description of Direct Treatment Cost After Incident Diagnosis in COPD-12, COPD-24 and COPD-36 Samples | Total costs for GP visits | 429 Euro per Person-year |
| COPD-12 - Fourth Line Therapy | Description of Direct Treatment Cost After Incident Diagnosis in COPD-12, COPD-24 and COPD-36 Samples | Total costs for pulmnologist visits | 185 Euro per Person-year |
| COPD-12 - Fourth Line Therapy | Description of Direct Treatment Cost After Incident Diagnosis in COPD-12, COPD-24 and COPD-36 Samples | Total costs for other outpatient specialist visits | 565 Euro per Person-year |
| COPD-12 - Fourth Line Therapy | Description of Direct Treatment Cost After Incident Diagnosis in COPD-12, COPD-24 and COPD-36 Samples | Inpatient cost (all-cause) | 5508 Euro per Person-year |
| COPD-12 - Fourth Line Therapy | Description of Direct Treatment Cost After Incident Diagnosis in COPD-12, COPD-24 and COPD-36 Samples | Total cost for hospitalizations with COPD-exacerbations | 414 Euro per Person-year |
| COPD-12 - Fourth Line Therapy | Description of Direct Treatment Cost After Incident Diagnosis in COPD-12, COPD-24 and COPD-36 Samples | Total costs for hospitalizations with any COPD-diagnosis | 851 Euro per Person-year |
Secondary
Number of Patients With Long Term Oxygen Therapy (LTOT) in COPD-12, COPD-24 and COPD-36 Samples
Description of health-care resource use in the first 12/24/36 months after incident diagnosis - Number of Patients with Long Term Oxygen Therapy (LTOT).
Time frame: Up to 12, 24 and 36 months after index date for COPD-12, COPD-24 and COPD-36 sample respectively.
Population: Patients with newly diagnosed (incident) chronic obstructive pulmonary disease (COPD). Incident COPD-patients were reported by follow-up time (12, 24 and 36 months).
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| COPD-12 - First Line Therapy | Number of Patients With Long Term Oxygen Therapy (LTOT) in COPD-12, COPD-24 and COPD-36 Samples | 2338 Participants |
| COPD-12 - Second Line Therapy | Number of Patients With Long Term Oxygen Therapy (LTOT) in COPD-12, COPD-24 and COPD-36 Samples | 1696 Participants |
| COPD-12 - Third Line Therapy | Number of Patients With Long Term Oxygen Therapy (LTOT) in COPD-12, COPD-24 and COPD-36 Samples | 741 Participants |
Secondary
Number of Yearly Hospitalizations in COPD-12, COPD-24 and COPD-36 Samples
Description of health-care resource use in the first 12/24/36 months after incident diagnosis: Number of yearly hospitalizations (inpatient treatment). Following categories of inpatient treatment are reported: Number of yearly hospitalizations with exacerbations (J44.1); Number of yearly hospitalizations with exacerbations, any COPD diagnosis (J44); Number of yearly hospitalizations with non-COPD diagnosis. Results are reported by follow-up time and available Disease Management Program (DMP) data.
Time frame: Up to 12, 24 and 36 months after index date for COPD-12, COPD-24 and COPD-36 sample respectively.
Population: Patients with newly diagnosed (incident) chronic obstructive pulmonary disease (COPD). Incident COPD-patients were reported by follow-up time (12, 24 and 36 months) and available Disease Management Program (DMP) data. Arms are not mutually exclusive.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| COPD-12 - First Line Therapy | Number of Yearly Hospitalizations in COPD-12, COPD-24 and COPD-36 Samples | Yearly hospitalizations - any COPD diagnosis (J44) | 0.17 Yearly hospitalizations | Standard Deviation 0.45 |
| COPD-12 - First Line Therapy | Number of Yearly Hospitalizations in COPD-12, COPD-24 and COPD-36 Samples | Yearly hospitalizations with exacerbation (J44.1) | 0.09 Yearly hospitalizations | Standard Deviation 0.34 |
| COPD-12 - First Line Therapy | Number of Yearly Hospitalizations in COPD-12, COPD-24 and COPD-36 Samples | Yearly hospitalizatons with non-COPD diagnosis | 2.02 Yearly hospitalizations | Standard Deviation 2.08 |
| COPD-12 - Second Line Therapy | Number of Yearly Hospitalizations in COPD-12, COPD-24 and COPD-36 Samples | Yearly hospitalizations - any COPD diagnosis (J44) | 0.10 Yearly hospitalizations | Standard Deviation 0.28 |
| COPD-12 - Second Line Therapy | Number of Yearly Hospitalizations in COPD-12, COPD-24 and COPD-36 Samples | Yearly hospitalizations with exacerbation (J44.1) | 0.06 Yearly hospitalizations | Standard Deviation 0.22 |
| COPD-12 - Second Line Therapy | Number of Yearly Hospitalizations in COPD-12, COPD-24 and COPD-36 Samples | Yearly hospitalizatons with non-COPD diagnosis | 1.38 Yearly hospitalizations | Standard Deviation 1.46 |
| COPD-12 - Third Line Therapy | Number of Yearly Hospitalizations in COPD-12, COPD-24 and COPD-36 Samples | Yearly hospitalizations - any COPD diagnosis (J44) | 0.08 Yearly hospitalizations | Standard Deviation 0.21 |
| COPD-12 - Third Line Therapy | Number of Yearly Hospitalizations in COPD-12, COPD-24 and COPD-36 Samples | Yearly hospitalizations with exacerbation (J44.1) | 0.04 Yearly hospitalizations | Standard Deviation 0.16 |
| COPD-12 - Third Line Therapy | Number of Yearly Hospitalizations in COPD-12, COPD-24 and COPD-36 Samples | Yearly hospitalizatons with non-COPD diagnosis | 1.17 Yearly hospitalizations | Standard Deviation 1.22 |
| COPD-12 - Fourth Line Therapy | Number of Yearly Hospitalizations in COPD-12, COPD-24 and COPD-36 Samples | Yearly hospitalizations - any COPD diagnosis (J44) | 0.18 Yearly hospitalizations | Standard Deviation 0.44 |
| COPD-12 - Fourth Line Therapy | Number of Yearly Hospitalizations in COPD-12, COPD-24 and COPD-36 Samples | Yearly hospitalizations with exacerbation (J44.1) | 0.11 Yearly hospitalizations | Standard Deviation 0.35 |
| COPD-12 - Fourth Line Therapy | Number of Yearly Hospitalizations in COPD-12, COPD-24 and COPD-36 Samples | Yearly hospitalizatons with non-COPD diagnosis | 1.09 Yearly hospitalizations | Standard Deviation 1.54 |
| COPD-24 Sample With DMP Data | Number of Yearly Hospitalizations in COPD-12, COPD-24 and COPD-36 Samples | Yearly hospitalizations - any COPD diagnosis (J44) | 0.12 Yearly hospitalizations | Standard Deviation 0.3 |
| COPD-24 Sample With DMP Data | Number of Yearly Hospitalizations in COPD-12, COPD-24 and COPD-36 Samples | Yearly hospitalizations with exacerbation (J44.1) | 0.07 Yearly hospitalizations | Standard Deviation 0.24 |
| COPD-24 Sample With DMP Data | Number of Yearly Hospitalizations in COPD-12, COPD-24 and COPD-36 Samples | Yearly hospitalizatons with non-COPD diagnosis | 0.84 Yearly hospitalizations | Standard Deviation 1.06 |
| COPD-36 Sample With DMP Data | Number of Yearly Hospitalizations in COPD-12, COPD-24 and COPD-36 Samples | Yearly hospitalizations with exacerbation (J44.1) | 0.05 Yearly hospitalizations | Standard Deviation 0.15 |
| COPD-36 Sample With DMP Data | Number of Yearly Hospitalizations in COPD-12, COPD-24 and COPD-36 Samples | Yearly hospitalizatons with non-COPD diagnosis | 0.74 Yearly hospitalizations | Standard Deviation 0.95 |
| COPD-36 Sample With DMP Data | Number of Yearly Hospitalizations in COPD-12, COPD-24 and COPD-36 Samples | Yearly hospitalizations - any COPD diagnosis (J44) | 0.09 Yearly hospitalizations | Standard Deviation 0.21 |
Secondary
Number of Yearly Visits Per Outpatient Treatment in COPD-12, COPD-24 and COPD-36 Samples
Description of health-care resource use (HCRU) in the first 12/24/36 months after incident diagnosis - Number of yearly visits (outpatient treatment). Following categories are reported: Number of yearly general practitioner (GP) visits; Number of yearly pulmonologist visits; Number of yearly other specialist (primarily Ophthalmologist, Ear, Nose and Throat (ENT) specialist and Orthopedist) visits. Reported is the average number of yearly visits, per observed patient year.
Time frame: Up to 12, 24 and 36 months after index date for COPD-12, COPD-24 and COPD-36 sample respectively.
Population: Patients with newly diagnosed (incident) chronic obstructive pulmonary disease (COPD). Incident COPD-patients were reported by follow-up time (COPD-12, COPD-24, COPD-36) and available Disease Management Program (DMP) data. Arms are not mutually exclusive.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| COPD-12 - First Line Therapy | Number of Yearly Visits Per Outpatient Treatment in COPD-12, COPD-24 and COPD-36 Samples | Number of yearly GP visits | 4.58 Yearly visits | Standard Deviation 1.91 |
| COPD-12 - First Line Therapy | Number of Yearly Visits Per Outpatient Treatment in COPD-12, COPD-24 and COPD-36 Samples | Number of yearly other specialist visits | 7.73 Yearly visits | Standard Deviation 5.84 |
| COPD-12 - First Line Therapy | Number of Yearly Visits Per Outpatient Treatment in COPD-12, COPD-24 and COPD-36 Samples | Number of yearly pulmonologist visits | 1.08 Yearly visits | Standard Deviation 1.57 |
| COPD-12 - Second Line Therapy | Number of Yearly Visits Per Outpatient Treatment in COPD-12, COPD-24 and COPD-36 Samples | Number of yearly GP visits | 4.48 Yearly visits | Standard Deviation 1.69 |
| COPD-12 - Second Line Therapy | Number of Yearly Visits Per Outpatient Treatment in COPD-12, COPD-24 and COPD-36 Samples | Number of yearly other specialist visits | 7.66 Yearly visits | Standard Deviation 5.5 |
| COPD-12 - Second Line Therapy | Number of Yearly Visits Per Outpatient Treatment in COPD-12, COPD-24 and COPD-36 Samples | Number of yearly pulmonologist visits | 1.00 Yearly visits | Standard Deviation 1.37 |
| COPD-12 - Third Line Therapy | Number of Yearly Visits Per Outpatient Treatment in COPD-12, COPD-24 and COPD-36 Samples | Number of yearly pulmonologist visits | 0.92 Yearly visits | Standard Deviation 1.27 |
| COPD-12 - Third Line Therapy | Number of Yearly Visits Per Outpatient Treatment in COPD-12, COPD-24 and COPD-36 Samples | Number of yearly GP visits | 4.45 Yearly visits | Standard Deviation 1.61 |
| COPD-12 - Third Line Therapy | Number of Yearly Visits Per Outpatient Treatment in COPD-12, COPD-24 and COPD-36 Samples | Number of yearly other specialist visits | 7.67 Yearly visits | Standard Deviation 5.35 |
| COPD-12 - Fourth Line Therapy | Number of Yearly Visits Per Outpatient Treatment in COPD-12, COPD-24 and COPD-36 Samples | Number of yearly GP visits | 4.30 Yearly visits | Standard Deviation 1.91 |
| COPD-12 - Fourth Line Therapy | Number of Yearly Visits Per Outpatient Treatment in COPD-12, COPD-24 and COPD-36 Samples | Number of yearly other specialist visits | 8.11 Yearly visits | Standard Deviation 5.84 |
| COPD-12 - Fourth Line Therapy | Number of Yearly Visits Per Outpatient Treatment in COPD-12, COPD-24 and COPD-36 Samples | Number of yearly pulmonologist visits | 2.76 Yearly visits | Standard Deviation 1.57 |
Secondary
Percentage of Incident COPD-patients With Initial Treatment Not in Line Treatment Guideline - COPD-12 Sample
Percentage of incident chronic obstructive pulmonary disease (COPD) patients with initial drug treatment not in line with 2012/2018 german guidelines. Results are reported for COPD-12 sample. According to guidelines the initial treatment with long-acting bronchodilators should generally not include use of Inhaled corticosteroids (ICS) (both guidelines). Based on the 2012 guideline, a therapy with long-acting bronchodilators should not start with a combination of Long-acting beta agonist (LABA) + Long-acting muscarinic antagonist (LAMA) or triple therapy of LAMA+LABA+ ICS.
Time frame: At index date.
Population: All patients with newly diagnosed chronic obstructive pulmonary disease (COPD), with a follow-up of 12 months since index date (COPD-12).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| COPD-12 - First Line Therapy | Percentage of Incident COPD-patients With Initial Treatment Not in Line Treatment Guideline - COPD-12 Sample | Any ICS containing therapy | 14.1 Percentage of Patients |
| COPD-12 - First Line Therapy | Percentage of Incident COPD-patients With Initial Treatment Not in Line Treatment Guideline - COPD-12 Sample | LAMA + LABA combination | 22.7 Percentage of Patients |
| COPD-12 - First Line Therapy | Percentage of Incident COPD-patients With Initial Treatment Not in Line Treatment Guideline - COPD-12 Sample | LABA + LAMA + ICS | 4.7 Percentage of Patients |
Secondary
Percentage of Incident COPD-patients With Treatment Not in Line Treatment Guideline - COPD-12 Sample (Escalation Therapy)
Percentage of incident chronic obstructive pulmonary disease (COPD) patients with drug treatment not in line with 2012/2018 german guidelines. Results are reported for patients in COPD-12 sample, with treatment escalation (mono therapy to Long-acting beta agonist (LABA)/ Long-acting muscarinic antagonist (LAMA)/ Inhaled corticosteroids (ICS), LABA/ICS or LAMA/LABA to LABA/LAMA/ICS) within the first 12 months after index date. According to guidelines patients should not receive a treatment intensification without any previous visit of a pneumologist or hospital (same quarter or previous quarter).
Time frame: Up to 12 months after index date.
Population: All patients in the COPD-12 sample with treatment escalation in the first 12 months after index date.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| COPD-12 - First Line Therapy | Percentage of Incident COPD-patients With Treatment Not in Line Treatment Guideline - COPD-12 Sample (Escalation Therapy) | 13 Percentage of Patients |
Secondary
Percentage of Incident COPD-patients With Treatment Not in Line Treatment Guideline - COPD-12 Sample (Triple Therapy)
Percentage of incident chronic obstructive pulmonary disease (COPD) patients with drug treatment not in line with 2012/2018 german guidelines. Results are reported for COPD-12 sample, who received triple therapy (Long-acting beta agonist (LABA) + Long-acting muscarinic antagonist (LAMA) + Inhaled corticosteroids (ICS)) within the first 12 months after incident diagnosis. According to both guidelines (2012/2018) a triple combination treatment should not be prescribed if only 1 or less confirmed outpatient diagnoses and no inpatient diagnosis of a COPD exacerbation (ICD-10 J44.1) before date of prescription of a triple therapy. FEV1: Forced expiratory volume (in 1 second).
Time frame: At first day of triple therapy prescription, (which is not the index date), up to 12 months.
Population: All patients included in the COPD-12 sample, who received triple therapy within the first 12 months after incident COPD.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| COPD-12 - First Line Therapy | Percentage of Incident COPD-patients With Treatment Not in Line Treatment Guideline - COPD-12 Sample (Triple Therapy) | ≤1 Outpatient diagnosis and no inpatient diagnosis indicating COPD related exacerbation | 69 Percentage of Patients |
| COPD-12 - First Line Therapy | Percentage of Incident COPD-patients With Treatment Not in Line Treatment Guideline - COPD-12 Sample (Triple Therapy) | Documented FEV1 ≥50% value | 75 Percentage of Patients |
Secondary
Percentage of Patients With Exacerbations After Incident Diagnosis in COPD-12, COPD-24, COPD-36 and COPD-FULL Samples
Description of exacerbation (severe exacerbations associated with hospitalizations) frequency of patients with newly diagnosed (incident) chronic obstructive pulmonary disease (COPD) in the first 12, 24, 36 and 48 months after incident diagnosis. Reported is the percentage of patients with exacerbations by the following categories: More or equal than one exacerbation (≥ 1) ; 1. exacerbation; 2. exacerbations; 3. exacerbations; more than 3 exacerbations (\> 3 exacerbations).
Time frame: Up to 12,24, 36 and 48 months after index date, for COPD-12, COPD-24, COPD-36 and COPD-FULL sample respectively.
Population: All patients with newly diagnosed (incident) chronic obstructive pulmonary disease. Incident COPD-patients were reported by follow-up time (12, 24, 36 and 48 months), arms are not mutually exclusive.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| COPD-12 - First Line Therapy | Percentage of Patients With Exacerbations After Incident Diagnosis in COPD-12, COPD-24, COPD-36 and COPD-FULL Samples | 3 exacerabation | 0.4 Percentage of participants |
| COPD-12 - First Line Therapy | Percentage of Patients With Exacerbations After Incident Diagnosis in COPD-12, COPD-24, COPD-36 and COPD-FULL Samples | 1 exacerbation | 9.8 Percentage of participants |
| COPD-12 - First Line Therapy | Percentage of Patients With Exacerbations After Incident Diagnosis in COPD-12, COPD-24, COPD-36 and COPD-FULL Samples | ≥ 3 exacerbation | 0.3 Percentage of participants |
| COPD-12 - First Line Therapy | Percentage of Patients With Exacerbations After Incident Diagnosis in COPD-12, COPD-24, COPD-36 and COPD-FULL Samples | 2 exacerbation | 1.5 Percentage of participants |
| COPD-12 - First Line Therapy | Percentage of Patients With Exacerbations After Incident Diagnosis in COPD-12, COPD-24, COPD-36 and COPD-FULL Samples | ≥ 1 exacerbation | 12.0 Percentage of participants |
| COPD-12 - Second Line Therapy | Percentage of Patients With Exacerbations After Incident Diagnosis in COPD-12, COPD-24, COPD-36 and COPD-FULL Samples | 2 exacerbation | 1.4 Percentage of participants |
| COPD-12 - Second Line Therapy | Percentage of Patients With Exacerbations After Incident Diagnosis in COPD-12, COPD-24, COPD-36 and COPD-FULL Samples | 3 exacerabation | 0.4 Percentage of participants |
| COPD-12 - Second Line Therapy | Percentage of Patients With Exacerbations After Incident Diagnosis in COPD-12, COPD-24, COPD-36 and COPD-FULL Samples | ≥ 3 exacerbation | 0.3 Percentage of participants |
| COPD-12 - Second Line Therapy | Percentage of Patients With Exacerbations After Incident Diagnosis in COPD-12, COPD-24, COPD-36 and COPD-FULL Samples | 1 exacerbation | 8.0 Percentage of participants |
| COPD-12 - Second Line Therapy | Percentage of Patients With Exacerbations After Incident Diagnosis in COPD-12, COPD-24, COPD-36 and COPD-FULL Samples | ≥ 1 exacerbation | 10.1 Percentage of participants |
| COPD-12 - Third Line Therapy | Percentage of Patients With Exacerbations After Incident Diagnosis in COPD-12, COPD-24, COPD-36 and COPD-FULL Samples | 2 exacerbation | 1.7 Percentage of participants |
| COPD-12 - Third Line Therapy | Percentage of Patients With Exacerbations After Incident Diagnosis in COPD-12, COPD-24, COPD-36 and COPD-FULL Samples | ≥ 1 exacerbation | 11.0 Percentage of participants |
| COPD-12 - Third Line Therapy | Percentage of Patients With Exacerbations After Incident Diagnosis in COPD-12, COPD-24, COPD-36 and COPD-FULL Samples | 1 exacerbation | 8.5 Percentage of participants |
| COPD-12 - Third Line Therapy | Percentage of Patients With Exacerbations After Incident Diagnosis in COPD-12, COPD-24, COPD-36 and COPD-FULL Samples | 3 exacerabation | 0.4 Percentage of participants |
| COPD-12 - Third Line Therapy | Percentage of Patients With Exacerbations After Incident Diagnosis in COPD-12, COPD-24, COPD-36 and COPD-FULL Samples | ≥ 3 exacerbation | 0.4 Percentage of participants |
| COPD-12 - Fourth Line Therapy | Percentage of Patients With Exacerbations After Incident Diagnosis in COPD-12, COPD-24, COPD-36 and COPD-FULL Samples | 3 exacerabation | 0.5 Percentage of participants |
| COPD-12 - Fourth Line Therapy | Percentage of Patients With Exacerbations After Incident Diagnosis in COPD-12, COPD-24, COPD-36 and COPD-FULL Samples | 1 exacerbation | 9.5 Percentage of participants |
| COPD-12 - Fourth Line Therapy | Percentage of Patients With Exacerbations After Incident Diagnosis in COPD-12, COPD-24, COPD-36 and COPD-FULL Samples | ≥ 1 exacerbation | 12.2 Percentage of participants |
| COPD-12 - Fourth Line Therapy | Percentage of Patients With Exacerbations After Incident Diagnosis in COPD-12, COPD-24, COPD-36 and COPD-FULL Samples | 2 exacerbation | 1.8 Percentage of participants |
| COPD-12 - Fourth Line Therapy | Percentage of Patients With Exacerbations After Incident Diagnosis in COPD-12, COPD-24, COPD-36 and COPD-FULL Samples | ≥ 3 exacerbation | 0.4 Percentage of participants |
Secondary
Prescription of Medication in COPD-12, COPD-24 and COPD-36 Samples
Description of health-care resource use in the first 12/24/36 months after incident diagnosis - Prescription of medication. Top-5 prescription of non-COPD medication: Beta-blocking agents; Anti-thrombotic agents; Other analgesics & antipyretics; High-ceiling diuretics; Drugs for peptic ulcer or Gastroesophageal reflux disease (GERD). Other prescriptions: Antibiotics for systemic use (ATC J02AA); Antibiotics + corticosteroids (ATC D07C). Reported is number of yearly prescription.
Time frame: Up to 12, 24 and 36 months after index date for COPD-12, COPD-24 and COPD-36 sample respectively.
Population: Patients with newly diagnosed (incident) chronic obstructive pulmonary disease (COPD). Incident COPD-patients were reported by follow-up time (12, 24 and 36 months). Arms are not mutually exclusive.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| COPD-12 - First Line Therapy | Prescription of Medication in COPD-12, COPD-24 and COPD-36 Samples | Anti-thrombotic agents | 2.06 Yearly prescription (of medication) | Standard Deviation 3 |
| COPD-12 - First Line Therapy | Prescription of Medication in COPD-12, COPD-24 and COPD-36 Samples | Drugs for peptic ulcer or GERD | 1.59 Yearly prescription (of medication) | Standard Deviation 2.11 |
| COPD-12 - First Line Therapy | Prescription of Medication in COPD-12, COPD-24 and COPD-36 Samples | High-ceiling diuretics | 1.80 Yearly prescription (of medication) | Standard Deviation 2.55 |
| COPD-12 - First Line Therapy | Prescription of Medication in COPD-12, COPD-24 and COPD-36 Samples | Beta-blocking agents | 2.21 Yearly prescription (of medication) | Standard Deviation 2.49 |
| COPD-12 - First Line Therapy | Prescription of Medication in COPD-12, COPD-24 and COPD-36 Samples | Antibiotics + corticosteroids (ATC D07C) | 0.03 Yearly prescription (of medication) | Standard Deviation 0.29 |
| COPD-12 - First Line Therapy | Prescription of Medication in COPD-12, COPD-24 and COPD-36 Samples | Antibiotics for systemic use | 0 Yearly prescription (of medication) | Standard Deviation 0 |
| COPD-12 - First Line Therapy | Prescription of Medication in COPD-12, COPD-24 and COPD-36 Samples | Other analgesics & antipyretics | 1.07 Yearly prescription (of medication) | Standard Deviation 2.81 |
| COPD-12 - Second Line Therapy | Prescription of Medication in COPD-12, COPD-24 and COPD-36 Samples | High-ceiling diuretics | 1.67 Yearly prescription (of medication) | Standard Deviation 2.33 |
| COPD-12 - Second Line Therapy | Prescription of Medication in COPD-12, COPD-24 and COPD-36 Samples | Beta-blocking agents | 2.16 Yearly prescription (of medication) | Standard Deviation 2.35 |
| COPD-12 - Second Line Therapy | Prescription of Medication in COPD-12, COPD-24 and COPD-36 Samples | Anti-thrombotic agents | 1.87 Yearly prescription (of medication) | Standard Deviation 2.37 |
| COPD-12 - Second Line Therapy | Prescription of Medication in COPD-12, COPD-24 and COPD-36 Samples | Other analgesics & antipyretics | 1.01 Yearly prescription (of medication) | Standard Deviation 2.43 |
| COPD-12 - Second Line Therapy | Prescription of Medication in COPD-12, COPD-24 and COPD-36 Samples | Drugs for peptic ulcer or GERD | 1.56 Yearly prescription (of medication) | Standard Deviation 1.94 |
| COPD-12 - Second Line Therapy | Prescription of Medication in COPD-12, COPD-24 and COPD-36 Samples | Antibiotics for systemic use | 0.01 Yearly prescription (of medication) | Standard Deviation 0.02 |
| COPD-12 - Second Line Therapy | Prescription of Medication in COPD-12, COPD-24 and COPD-36 Samples | Antibiotics + corticosteroids (ATC D07C) | 0.03 Yearly prescription (of medication) | Standard Deviation 0.24 |
| COPD-12 - Third Line Therapy | Prescription of Medication in COPD-12, COPD-24 and COPD-36 Samples | Drugs for peptic ulcer or GERD | 1.58 Yearly prescription (of medication) | Standard Deviation 1.88 |
| COPD-12 - Third Line Therapy | Prescription of Medication in COPD-12, COPD-24 and COPD-36 Samples | Anti-thrombotic agents | 1.80 Yearly prescription (of medication) | Standard Deviation 2.16 |
| COPD-12 - Third Line Therapy | Prescription of Medication in COPD-12, COPD-24 and COPD-36 Samples | Antibiotics + corticosteroids (ATC D07C) | 0.03 Yearly prescription (of medication) | Standard Deviation 0.19 |
| COPD-12 - Third Line Therapy | Prescription of Medication in COPD-12, COPD-24 and COPD-36 Samples | Antibiotics for systemic use | 0 Yearly prescription (of medication) | Standard Deviation 0 |
| COPD-12 - Third Line Therapy | Prescription of Medication in COPD-12, COPD-24 and COPD-36 Samples | High-ceiling diuretics | 1.55 Yearly prescription (of medication) | Standard Deviation 2.21 |
| COPD-12 - Third Line Therapy | Prescription of Medication in COPD-12, COPD-24 and COPD-36 Samples | Other analgesics & antipyretics | 0.93 Yearly prescription (of medication) | Standard Deviation 2.19 |
| COPD-12 - Third Line Therapy | Prescription of Medication in COPD-12, COPD-24 and COPD-36 Samples | Beta-blocking agents | 2.15 Yearly prescription (of medication) | Standard Deviation 2.29 |
Secondary
Time From Index Date Until First Exacerbation - COPD-FULL, COPD-12, COPD-24 and COPD-36
Time from index date until first exacerbation, in the first 12/24/36/48 months after incident diagnosis. Only severe exacerbations leading to an inpatient hospitalization after index date (documented as main diagnosis: ICD-10 J44.1) are considered.
Time frame: Up to 12, 24, 36 and 48 months after index date for COPD-12, COPD-24, COPD-36 and COPD-FULL sample respectively.
Population: All patients with newly diagnosed (incident) chronic obstructive pulmonary disease. Incident COPD-patients were reported by follow-up time (12, 24, 36 and 48 months). Only patients with severe exacerbation leading to an inpatient hospitalization are included. Arms are not mutually exclusive.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| COPD-12 - First Line Therapy | Time From Index Date Until First Exacerbation - COPD-FULL, COPD-12, COPD-24 and COPD-36 | 42.8 Months | Standard Error 0.1 |
| COPD-12 - Second Line Therapy | Time From Index Date Until First Exacerbation - COPD-FULL, COPD-12, COPD-24 and COPD-36 | 42.9 Months | Standard Error 0.1 |
| COPD-12 - Third Line Therapy | Time From Index Date Until First Exacerbation - COPD-FULL, COPD-12, COPD-24 and COPD-36 | 43.3 Months | Standard Error 0.2 |
| COPD-12 - Fourth Line Therapy | Time From Index Date Until First Exacerbation - COPD-FULL, COPD-12, COPD-24 and COPD-36 | 43.5 Months | Standard Error 0.2 |
Secondary
Time From Index Date Until Start of Long-term Oxygen Therapy (LTOT) - COPD-12, COPD-24 and COPD-36 Samples
Time from index date until start of long-term oxygen therapy (LTOT) in days in the first 12/24/36 months after incident diagnosis.
Time frame: Up to 12, 24 and 36 months after index date for COPD-12, COPD-24 and COPD-36 sample respectively.
Population: Patients with newly diagnosed (incident) chronic obstructive pulmonary disease (COPD). Incident COPD-patients were reported by follow-up time (12, 24 and 36 months) and available Disease Management Program (DMP) data. Only patients with any observed LTOT are included.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| COPD-12 - First Line Therapy | Time From Index Date Until Start of Long-term Oxygen Therapy (LTOT) - COPD-12, COPD-24 and COPD-36 Samples | 68.9 Days | Standard Deviation 99.6 |
| COPD-12 - Second Line Therapy | Time From Index Date Until Start of Long-term Oxygen Therapy (LTOT) - COPD-12, COPD-24 and COPD-36 Samples | 160.2 Days | Standard Deviation 214.4 |
| COPD-12 - Third Line Therapy | Time From Index Date Until Start of Long-term Oxygen Therapy (LTOT) - COPD-12, COPD-24 and COPD-36 Samples | 88.6 Days | Standard Deviation 206.8 |
| COPD-12 - Fourth Line Therapy | Time From Index Date Until Start of Long-term Oxygen Therapy (LTOT) - COPD-12, COPD-24 and COPD-36 Samples | 64.5 Days | Standard Deviation 100.4 |
| COPD-24 Sample With DMP Data | Time From Index Date Until Start of Long-term Oxygen Therapy (LTOT) - COPD-12, COPD-24 and COPD-36 Samples | 159.1 Days | Standard Deviation 216.2 |
| COPD-36 Sample With DMP Data | Time From Index Date Until Start of Long-term Oxygen Therapy (LTOT) - COPD-12, COPD-24 and COPD-36 Samples | 202.1 Days | Standard Deviation 294.6 |
Secondary
Time to First All-cause Hospitalization in COPD-12, COPD-24, COPD-36 Samples
Description of health-care resource use in the first 12/24/36 months after incident diagnosis in patients with chronic obstructive pulmonary disease (COPD). Reported is time to first all-cause hospitalization in days (inpatient treatment).
Time frame: Up to 12, 24 and 36 months after index date for COPD-12, COPD-24 and COPD-36 sample respectively.
Population: Patients with newly diagnosed (incident) chronic obstructive pulmonary disease (COPD). Incident COPD-patients were reported by follow-up time (12, 24 and 36 months) and available Disease Management Program (DMP) data. Arms are not mutually exclusive.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| COPD-12 - First Line Therapy | Time to First All-cause Hospitalization in COPD-12, COPD-24, COPD-36 Samples | 123 Days |
| COPD-12 - Second Line Therapy | Time to First All-cause Hospitalization in COPD-12, COPD-24, COPD-36 Samples | 207 Days |
| COPD-12 - Third Line Therapy | Time to First All-cause Hospitalization in COPD-12, COPD-24, COPD-36 Samples | 287 Days |
| COPD-12 - Fourth Line Therapy | Time to First All-cause Hospitalization in COPD-12, COPD-24, COPD-36 Samples | 141 Days |